Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Akebia Therapeutics Inc (AKBA) Sells Partial US Rights For Vadadustat To Otsuka

Akebia Therapeutics Inc (NASDAQ:AKBA) has surrendered 50% of U.S. commercialization rights to its oral anemia drug candidate vadadustat to Otsuka Pharmaceutical, a Japanese company. As such, Akebia is expecting $265 million in funding from Otsuka in exchange for the rights. Of the pledged funding amount, $125 million is being paid upfront and $35 million will be released in 1Q17. The remaining $105 million will be released later.

The deal with Otsuka also makes Akebia eligible for milestone payments of up to $765 million. Though Akebia said the milestone payments are related to development and commercialization of vadadustat, it didn’t elaborate what will trigger them.

gene, dna, organism, microarray, health, green, life, human genome, biotechnology, genetic diseases, disease, molecular biology, modern medical, micro structure,

Yang Nan/Shutterstock.com

“This collaboration achieves our goal of funding our global PRO2TECT and INNO2VATE Phase 3 studies for vadadustat while retaining significant long-term value for Akebia,” said Akebia CEO John P. Butler.

Funding Phase 3 Trials

The investment from Otsuka will go into funding two Phase 3 studies of vadadustat. The first Phase 3 study of vadadustat began enrolling non-dialysis kidney disease patients in January and the program is expected to have reached full enrollment by the end of 2017. The second Phase 3 study is taking in dialysis patients and began enrollment in August and the target is to complete the enrollment by 1H18.

Akebia’s vadadustat is aimed at chronic kidney disease (CKD) patients. It works by stimulating the production of red blood cells and hemoglobin. With vadadustat, Akebia is hoping to replace Amgen, Inc. (NASDAQ:AMGN) Epogen in anemia treatment market. Epogen is an injectable drug, while vadadustat is an oral pill.

European Partnership

Akebia Therapeutics Inc (NASDAQ:AKBA) was looking for a European partner for vadadustat development when Otsuka showed up with its offer. The company continues to look for European deal for the drug. Akebia earlier sold Asian rights to vadadustat to Mitsubishi Tanabe Pharma, another Japanese company.

About $3.5 billion is spent annually on injectable anemia treatment in the U.S.

Competition For Market Share

But Akebia faces competition from FibroGen Inc (NASDAQ:FGEN) for anemia pills market. FibroGen is developing a rival drug called roxadustat with the same mechanism as vadadustat. Unlike Akebia, FibroGen has fully enrolled patients for its Phase 3 studies of roxadustat with results now expected in 2018. AstraZeneca plc (ADR) (NYSE:AZN) and Astellas Pharma NPV (OTCMKTS:ALPMF) are backing FibroGen’s roxadustat.

Akebia Therapeutics Inc (NASDAQ:AKBA) stock rose 19.4% to $9.97 in the last session, but the stock is down more than 22% since the beginning of the year.

Follow Akebia Therapeutics Inc. (NASDAQ:AKBA)
Trade (NASDAQ:AKBA) Now!

Note: This article is written by Andy Parker and originally published at Market Exclusive.